What is the relation between NAD+ and vitamin B3?
Vitamin B3 is the indispensable building block for NAD+ in the body, and that relationship is causal and well supported. Whether supplementation with modern forms such as NR or NMN demonstrably benefits healthy individuals has not yet been sufficiently proven; anyone considering supplementation would do well to wait for larger clinical studies and, if in doubt, consult a doctor.
NAD+ is a molecule the body cannot simply produce on its own: it requires vitamin B3 as a building block. Vitamin B3 is not a single substance but a family of related compounds: niacin (nicotinic acid), nicotinamide, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). All of these forms are so-called precursors, or raw materials, that cells can use to produce NAD+. An insufficient dietary intake of vitamin B3 therefore directly leads to an NAD+ deficiency in the body.
Why is adequate NAD+ so important? NAD+ is indispensable in hundreds of energy-yielding chemical reactions in the cell, including the functioning of the mitochondria (the cell's power plants). In addition, repair proteins such as sirtuins and PARPs (involved in DNA repair and the switching of genes on and off) consume NAD+ as a raw material. NAD+ is therefore both an energy molecule and a regulator of cellular health and DNA repair.
NAD+ levels measurably decline with age, and this pattern is linked to age-related deterioration. Whether restoring those levels through vitamin B3 supplementation actually reverses age-related complaints in humans has not yet been proven. There is a great deal of promising animal research, but the translation to clinical evidence in humans has only been made to a limited extent.
Of the available forms of vitamin B3, ordinary niacin has long been known and has shown promising results in animal research into severe muscle wasting in cancer (cachexia): it restored NAD+ levels in tissues and improved mitochondrial function in muscles. NR and NMN, the more modern and more expensive variants, are largely converted to nicotinamide in the liver before reaching other tissues when taken orally. This means that the route of intake strongly determines what the supplement actually does.
In humans, the data are still limited. A small clinical study involving 30 Parkinson's patients (1000 mg NR per day, 30 days) showed a variable increase in NAD+ in the brain, along with reduced inflammatory markers and a mild clinical improvement in the subgroup that actually produced more NAD+. In mouse models of Alzheimer's disease, five months of NR supplementation reduced brain inflammation and improved cognitive functioning. These are preliminary results from early clinical and animal research, not proof of efficacy.
Too little is still known about long-term safety. In the clinical Parkinson's study, NR was well tolerated, but experts emphasize that the role of the gut microbiome in processing these precursors, the way NAD+ functions in different cellular compartments, and less well-known breakdown pathways have not yet been sufficiently studied. An explicit warning is given that more fundamental research is needed before broad supplementation can be responsibly recommended in healthy individuals.
Based on multiple review articles and human studies (PMID 34041853, 29249689, 39026037, 33930322, 29685734, 37012289, 35235774, 34497121). The human clinical studies are small and limited in number; most of the functional evidence regarding disease treatment comes from animal models.